IZO:CC - Izotropic Releases First Video of Izoview
(TheNewswire)
VANCOUVER, BC – TheNewswire - January 9,2023 – Izotropic Corporation (“ Izotropic ” orthe “ Company ”) (CSE: IZO ) (OTC: IZOZF )(FSE: 1R3 ), a medical device company commercializing IzoView, adedicated breast CT (computed tomography) imaging platform, for themore accurate detection and diagnosis of breast cancers, is pleased torelease the first video showcasing the completed engineering ofIzoView. This video is the first in a series of presentations,interviews, and demonstrations of IzoView and its capabilities.
The video featuring Chief Operating Officer Dr. YounesAchkire, and Head of Imaging Technology Dr. Andrew Hernandez willlaunch on the Company’s YouTube channel today, Monday, January9 th ,at 8:00 am PST. Shareholders can watch at the following link:
"I am thrilled and proud of our team for achievingthis critical milestone. It is a very exciting time forIzotropic!" – Dr. Younes Achkire, COO.
The team will be converging in Sacramento at theCompany’s engineering facility from the 15 th to the23 rd of January to outfit the facility in preparation for clinical andinvestment-related presentations and to complete a second phase ofinterviews with key scientific and clinical team members, includingDr. John Boone, Dr. Shadi Shakeri, Dr. Craig Abbey, Dr. Younes Achkireand Dr. Andrew Hernandez.
Statement from Dr. John M. Boone,
Co-Founder & Director ofIzotropic & Founder of IzoView Breast CT Technology
“I am a radiology professor and have lectured mystudents every year on how computed tomography is better thanradiography for detection of subtle findings – textbook dogma. Oneday in the late 1990's I sat down with a physicist friend and asked,"How can we really improve the detection and diagnosis of breastcancer?" Before he answered, I smiled, snapped my fingers, andsaid, "breast CT!".
Over a quarter century after that revelation – havingbuilt and tested four prototype breast CT scanners in my lab with thehelp of students, staff, post-docs, other medical physicists,radiologists, clinical coordinators, technologists, patients, and lotsof research funding, the amazing team of engineers at Izotropic hasdesigned and built the first commercial breast CT scanner that stemsfrom the research experience gained in my laboratory at UC Davis. Inmy long academic career, breast CT represents my life's most importantscientific achievement, especially in terms of its impact on women'slives. When our clinical trials started, I looked at the breast CTimages with my colleague radiologists, and they would tell me howthese 3D images would better inform their diagnostic capabilities. Itwas their enthusiasm and my nerdy passion for CT technology that keptme going on this long endeavor to better understand the physics ofbreast CT, its role in clinical practice, and how to optimize thebreast CT machine to maximize its impact in that role.
As the Co-Founder of Izotropic, I know that we facechallenges like any small company trying to bring a new breast imagingsystem to market. But in my 25+ years of research on breast CT withhundreds of women imaged on the UC Davis prototype scanners, I believein my heart that this technology will improve breast cancer diagnosesand, in the end, save lives. This belief is founded on decades ofcomputer and human observer perception researchon breast CT images. Bringing this technology to market represents thegoal of my professional life – I have a sister, a wife, daughters,and granddaughters, and what a rewarding feeling for me to improvetheir lives – and those of all women - should this horrid disease ofbreast cancer arrive at their doorstep.
Those dogmatic lectures on CT have proven to be truewith breast CT in our experience. I am so humbled that the men andwomen of Izotropic have taken our ideas from the UC Davis breast CTlab and turned them into a reality. The best is yet to come!”
ON BEHALF OF THE BOARD
Investor Relations Contact:
Mr. James Berard
Email: info@izocorp.com
Toll Free: 1-833-IZOCORP ext.1
Media Inquiries Contact:
Ms. Jaclyn Thast
Email: jaclyn@izocorp.com
Toll Free: 1-833-IZOCORP ext.3
About Izotropic Corporation
Izotropic Corporation is the only publicly tradedcompany commercializing a dedicated breast CT imaging platform,IzoView, for the more accurate detection and diagnosis of breastcancers. To expedite patient and provider access to IzoView,Izotropic's initial clinical study intends to demonstrate superiorperformance of diagnostic breast CT imaging over diagnosticmammography procedures. In follow-on clinical studies, Izotropicintends to validate platform applications, including breast screeningin radiology, treatment planning and monitoring in surgical oncology,and breast reconstruction and implant monitoring in plastic andreconstructive surgery.
More information about Izotropic Corporation can befound on its website at izocorp.com and by reviewing its profile on SEDAR at sedar.com.
Forward-Looking Statements
This document may contain statements that are"Forward-Looking Statements," which are based upon thecurrent estimates, assumptions, projections, and expectations of theCompany's management, business, and its knowledge of the relevantmarket and economic environment in which it operates. The Company hastried, where possible, to identify suchinformation and statements by using words such as"anticipate," "believe," "envision,""estimate," "expect," "intend,""may," "plan," "predict,""project," "target," "potential,""will," "would," "could,""should," "continue," "contemplate" andother similar expressions and derivations thereof in connection withany discussion of future events, trends or prospects or futureoperating or financial performance, although not all forward-lookingstatements contain these identifying words.
These statements are not guarantees of performance andinvolve risks, including those related to capital requirements anduncertainties that are difficult to control or predict, and as such,they may cause future results of the Company's activity to differsignificantly from the content and implications of such statements.Forward-Looking Statements are pertinent only as of the date on whichthey are made, and the Company undertakes no obligation to update orrevise any Forward-Looking Statements to reflect new information or the occurrence of future events orcircumstances unless otherwise required to do so by law. Neither theCompany nor its shareholders, officers, and consultants shall beliable for any action and the results of any action taken by anyperson based on the information contained herein, including, withoutlimitation the purchase or sale of Company securities. Nothing in thisdocument should be deemed to be medical or other advice of any kind.All images are for illustrative purposes only. IzoView is not yetapproved for sale.
Copyright (c) 2023 TheNewswire - All rights reserved.